← Leaderboards
Shunguang Wei
University Of Iowa
$4,842,264
Attributed
$4,842,264
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $970.8K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,842,264 · 2
By mechanism
R01$4,842,264 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Iowa
Same institution · by research overlap
- Robin L. Davisson$12,954,116
- Robert B Felder$11,797,640
- Justin L Grobe$8,891,606
- Huxing Cui$7,058,914
- Jon Resch$1,700,218
Others in their field
Other Emerging Leaders on “Inflammatory”
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$21,969,486
- Gary Fanger · Rise Therapeutics, Llc$20,823,569
- Gina Montealegre · Leidos Biomedical Research, Inc.$19,781,641
- Jeffrey Reich · Sparian Biosciences, Inc.$13,729,307
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
- James Dale Berry · Brigham And Women'S Hospital$11,004,714
Research focus
InflammatoryMetabolic DiseasesImmune ResponseInflammation MediatorsInfliximabInsightHeart FunctionHypothalamic StructureImmunocytochemistryCytokineEtanerceptHeart FailureFunctional DisorderInjectionsAnimalsElectrophysiology (Science)BrainHypertensionDiabetes MellitusCardiovascular DiseasesClinical TrialsCardiovascular SystemBiochemistryMolecular Biology
Grant awards (10)
Novel Role of Interleukin-17 in Sympathetic Activation in Heart Failure$589,561
R01 · FY2025 · HL · contact PI
Novel Role of Interleukin-17 in Sympathetic Activation in Heart Failure$577,770
R01 · FY2024 · HL · contact PI
Novel Role of Interleukin-17 in Sympathetic Activation in Heart Failure$589,561
R01 · FY2023 · HL · contact PI
Novel Role of Interleukin-17 in Sympathetic Activation in Heart Failure$589,561
R01 · FY2022 · HL · contact PI
Targeting TACE, a novel approach to the treatment of sympathetic excitation in heart failure.$381,250
R01 · FY2022 · HL · contact PI
Novel Role of Interleukin-17 in Sympathetic Activation in Heart Failure$589,561
R01 · FY2021 · HL · contact PI
Targeting TACE, a novel approach to the treatment of sympathetic excitation in heart failure.$381,250
R01 · FY2021 · HL · contact PI
Targeting TACE, a novel approach to the treatment of sympathetic excitation in heart failure.$381,250
R01 · FY2020 · HL · contact PI
Targeting TACE, a novel approach to the treatment of sympathetic excitation in heart failure.$381,250
R01 · FY2019 · HL · contact PI
Targeting TACE, a novel approach to the treatment of sympathetic excitation in heart failure.$381,250
R01 · FY2018 · HL · contact PI